RGLS vs. RIGL, ALIM, MACK, BOLT, EBS, XOMA, VNDA, VSTM, LXRX, and MCRB
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Rigel Pharmaceuticals (RIGL), Alimera Sciences (ALIM), Merrimack Pharmaceuticals (MACK), Bolt Biotherapeutics (BOLT), Emergent BioSolutions (EBS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
Regulus Therapeutics received 30 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 63.54% of users gave Regulus Therapeutics an outperform vote.
Rigel Pharmaceuticals has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Regulus Therapeutics has a net margin of 0.00% compared to Regulus Therapeutics' net margin of -16.45%. Regulus Therapeutics' return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Rigel Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Rigel Pharmaceuticals presently has a consensus target price of $5.81, indicating a potential upside of 497.01%. Regulus Therapeutics has a consensus target price of $7.25, indicating a potential upside of 253.66%. Given Regulus Therapeutics' higher possible upside, equities analysts plainly believe Rigel Pharmaceuticals is more favorable than Regulus Therapeutics.
In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Regulus Therapeutics. MarketBeat recorded 13 mentions for Rigel Pharmaceuticals and 11 mentions for Regulus Therapeutics. Regulus Therapeutics' average media sentiment score of 0.51 beat Rigel Pharmaceuticals' score of 0.35 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.
Summary
Rigel Pharmaceuticals beats Regulus Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
